PD-1 / HER2 bispecific antibody! Xinda biological tumor immunotherapy ibi315 completed the first patient administration in phase I clinical research!

November 27, 2019 / BIOON / -- innovent biologics is a biopharmaceutical company dedicated to R & D, production and sales of innovative drugs for the treatment of major diseases such as tumor, autoimmune and metabolic diseases Recently, the company and South Korea and the United States announced that the phase I clinical research of recombinant all human bispecific antibody (R & D Code: ibi315) for programmed death receptor 1 (PD-1) and human epidermal growth factor receptor 2 (HER2) jointly developed by the two sides has completed the first patient administration in China This study (cibi315a101) is a phase I clinical study conducted in China to evaluate the safety, tolerability, antitumor activity and phase II study recommended dose (rp2d) of ibi315 in patients with advanced solid tumors expressing HER2 Ibi315 is a recombinant all human IgG1 bispecific antibody, which may provide a new clinical treatment scheme for cancer patients with HER2 expression in the future Ibi315 can improve the antitumor activity and curative effect by blocking the HER2 signal pathway and PD-1 / PD-L1 signal pathway, bridging the T lymphocyte expressing PD-1 and the tumor cell expressing HER2 Dr Zhou Hui, vice president of medical science and strategic Oncology Department of Cinda biopharmaceutical group, said: "ibi315 is the first PD-1 / HER2 bispecific antibody entering the clinical development stage in the world, and it is an important product in the anti-tumor product pipeline of Cinda biopharmaceutical group Therefore, active development of ibi315 has important clinical value We hope that ibi315, a new dual antibody drug, can provide patients with a new and more effective treatment plan to meet a large number of clinical needs, so that more patients can benefit from it " Mr se Chang Kwon, President of Korea US Pharmaceutical Co., Ltd., said: "ibi315 is a bispecific antibody developed by adopting Korea us pentambodytm technology platform, which has successfully entered the clinical research stage We will continue to work closely with our partner, Cinda bio, to focus on R & D and further promote the clinical and commercial development of the project " About ibi315, ibi315 is jointly developed by Cinda biopharmaceutical and Korea US pharmaceutical, and is responsible for clinical development in China by Cinda biopharmaceutical Ibi315 is a recombinant all human IgG1 type anti-PD-1 / HER2 bispecific antibody Preclinical studies showed that ibi315 can bridge the T-lymphocytes expressing PD-1 and the tumor cells expressing HER2 through the double target specific binding, assist the T-cells to recognize and kill tumor cells, thus improving the anti-tumor activity Source: Xinda biology